Consequently, it has been proposed that either overexpression of MTF2 or inhibition of MDM2 sensitizes the leukemic cells to chemotherapeutics [83], offering a potential new strategy for treating AML patients. This evidence concerns the gene MDM2 and acute myeloid leukemia.